Par Calls Novartis' Lotrel Patent Unenforceable
Par Pharmaceutical Companies Inc. has fired off the latest salvo in its battle with Swiss pharmaceutical giant Novartis International AG over the billion-dollar hypertension drug Lotrel, asking a New Jersey court...To view the full article, register now.
Already a subscriber? Click here to view full article